LOS ANGELES, Aug. 26 (Xinhua) — U.S. pharmaceutical company Lilly announced Tuesday that its experimental oral GLP-1 receptor agonist, orforglipron, achieved positive results in a Phase 3 trial targeting adults with overweight and type 2 diabetes. Read full story
Date: 27 August, 2025 6:01 am
Source: thestar.com.my
💬 Join the Conversation! 💬
We’ve disabled comments on our posts and pages to keep the discussions organized and lively! But don’t worry – the conversation isn’t over. Head over to our forum and share your thoughts, ideas, and feedback with the community! It’s the perfect place to connect, learn, and engage with others who care about the same things. We can’t wait to hear from you!